A collection of articles, news releases, and events surrounding the development of Topsalysin or PRX302, as a treatment for localized prostate cancer and BPH.
Thanks to the many anonymous writers and posters at StockTwits who have contributed articles and links to information about Sophiris Bio Inc. and Topsalysin, as well as the skilled management of Sophiris Bio Inc. https://www.sophirisbio.com/about/management
March 10, 2020, Sophiris Bio Announces Nasdaq Delisting; https://www.otcmarkets.com/stock/SPHS/news?id=256120
November 18, 2019, Zacks Investment Research, Single Phase 3 Clinical Trial Planned For Topsalysin in Localized Prostate Cancer https://scr.zacks.com/News/Press-Releases/Press-Release-Details/2019/SPHS-Single-Phase-3-Clinical-Trial-Planned-for-Topsalysin-in-Localized-Prostate-Cancer-article/default.aspx
November 7, 2019, Sophiris Bio Reports Third Quarter 2019 Financial Results and Recent Corporate Highlights https://investor.sophirisbio.com/news-releases/news-release-details/sophiris-bio-reports-third-quarter-2019-financial-results-and
October 21, 2019, Sophiris Bio Receives Positive Feedback Regarding Phase 3 Localized Prostate Cancer Clinical Trial Design https://investor.sophirisbio.com/news-releases/news-release-details/sophiris-bio-receives-positive-feedback-fda-regarding-phase-3
September 9, 2019, H. C, Wainwright 21st Annual Global Investment Conference https://investor.sophirisbio.com/events/event-details/hc-wainwright-21st-annual-global-investment-conference
August 30, 2019, Sophiris Bio Announces Completion of $4.0 Million Direct Offering https://investor.sophirisbio.com/news-releases/news-release-details/sophiris-bio-announces-completion-40-million-registered-direct
August 27, 2019, Sophiris Bio Announces $4.0 Million Registered Direct Offering https://investor.sophirisbio.com/news-releases/news-release-details/sophiris-bio-announces-40-million-registered-direct-offering
August 13, 2019, DailyMail Article “3D SmartTarget Scan” Professors Hashim Ahmed and Mark Emberton https://www.dailymail.co.uk/health/article-7350757/3D-scan-smart-way-target-tiny-prostate-tumours.html
August 9, 2019, Sophiris Bio Reports 2nd Quarter 2019 Financial Results https://investor.sophirisbio.com/news-releases/news-release-details/sophiris-bio-reports-second-quarter-2019-financial-results-and
Notice of Annual General Meeting of Shareholders, June 27, 2019, 11:00 AM Location: Cooley LLP, 4401 Eastgate Mall, San Diego, California, 92121
June 19, 2019, Sophiris Bio Receives Positive Feedback from European Medicines Agency Regarding Phase III Localized Prostate Cancer Clinical Trial Design https://investor.sophirisbio.com/node/5816
June 19, 2019, Sophiris Bio Conference Call https://edge.media-server.com/m6/p/pgafvfgd
May 9, 2019, Sophiris Bio Reports First Quarter 2019 Financial Results https://investor.sophirisbio.com/news-releases/news-release-details/sophiris-bio-reports-first-quarter-2019-financial-results
April 10th, 2019, 18th Annual Needham Healthcare Conference, Randy Woods Presents, https://investor.sophirisbio.com/node/5821
April 8th H.C. Wainwright Global Life Sciences Conference, Randy Woods Presents, http://wsw.com/webcast/hcw4/sphs/index.aspx
March 18, 2019, HedgeFundHouse recent summary of Sophiris Bio activity. https://stocktwits.com/HedgeFundHouse/message/157540569
March 13, 2019, Sophiris Bio Reports Fourth Quarter 2018 and Year End Financial Results and Recent Corporate Highlights. https://investor.sophirisbio.com/news-releases/news-release-details/sophiris-bio-reports-fourth-quarter-2018-and-year-end-financial
March 7, 2019, Notes obtained from the United States Patent and Trademark Office regarding a patent application put forth on behalf of Sophiris. http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=/netahtml/PTO/srchnum.html&r=1&f=G&l=50&s1=20170333521.PGNR.&OS=DN/20170333521&RS=DN/20170333521 Further information regarding the above patent application can be found by entering patent # 15/418,571 at this page: https://portal.uspto.gov/pair/PublicPair Also at the above page click on the ” Image File Wrap” button for more documentation surrounding the history of this patent application.
January 3rd, 2019, Sophiris Bio 2019 Executive Bonus Plan http://www.conferencecalltranscripts.org/8/summary2/?id=5634105
December 18, 2018, SmarterAnalyst, Sophiris Receives Third Buy Rating in a Row https://www.smarteranalyst.com/brief/sophiris-bio-sphs-received-its-third-buy-in-a-row-2/
December 19, 2018, Zacks Small Cap Research, Sophiris Ready for Phase 3 https://scr.zacks.com/News/Press-Releases/Press-Release-Details/2018/SPHS-Ready-to-Move-Topsalysin-into-Phase-3-for-Localized-Clinically-Significant-Prostate-Cancer-article/default.aspx
December 17, 2018, 9:00 AM EDT Conference Call Archived Live https://investor.sophirisbio.com/node/5821
December 17, 2018, Sophiris Bio Provides Updates on P2b Localized Prostate Cancer Trial https://investor.sophirisbio.com/news-releases/news-release-details/sophiris-bio-provides-updates-phase-2b-localized-prostate-cancer
December 7, 2018, Form 424B5, Prospectus Outlining A $20Million Controlled Equity Offering, and Plan of Distribution. https://investor.sophirisbio.com/node/8506/html
November 27, 2018, Piper Jaffray Health Care Conference, Fireside Chat featuring Randy Woods, CEO Sophiris Bio. https://event.webcasts.com/viewer/event.jsp?ei=1221522&tp_key=60663448a0
November 20th, 2018, Zacks Small Cap Research Report, David Bautz PhD https://scr.zacks.com/News/Press-Releases/Press-Release-Details/2018/SPHS-Data-from-Second-Administration-of-Topsalysin-in-Phase-2b-Trial-Anticipated-Before-End-of-2018-article/default.aspx
November 13, 2018, Sophiris Bio Reports Third Quarter 2018 Financial Results and Recent Corporate Highlights. https://investor.sophirisbio.com/news-releases/news-release-details/sophiris-bio-reports-third-quarter-2018-financial-results-and
October 2, 2018, Live Corporate Overview – Cantor Global Health Conference http://wsw.com/webcast/cantor7/sphs/
Newly found patent application, https://patents.google.com/patent/WO2017132610A1/en
September 14, 2018, Sophiris Bio Extends the Interest Only Period under its Loan and Security Agreement http://investor.sophirisbio.com/news-releases/news-release-details/sophiris-bio-extends-interest-only-period-under-its-loan-and
September 5, 2018, H. C. Wainwright 20th Annual Investment Conference http://wsw.com/webcast/rrshq28/sphs/
August 2018: Sophiris Bio Investor Presentation http://investor.sophirisbio.com/static-files/f4ad8cbb-c1ba-4732-9f6f-9e4b1ae2758e
August 29, 2018: Sophiris Updates on Ph2b Prostate Cancer Trial http://investor.sophirisbio.com/news-releases/news-release-details/sophiris-bio-updates-phase-2b-localized-prostate-cancer-trial
August 14th, 2018, Second Quarter Report and Recent Corporate Highlights http://investor.sophirisbio.com/news-releases/news-release-details/sophiris-bio-reports-second-quarter-2018-financial-results-and
July 2, 2018, SBWire – BioMedReports: http://www.sbwire.com/press-releases/new-report-sheds-light-on-why-investors-are-accumulating-shares-of-sophiris-bio-and-transenterix-inc-1005442.htm
June 26, 2018, Sophiris ” worth sticking with” – Piper. Seeking Alpha Article https://seekingalpha.com/news/3366317-sophiris-worth-sticking-piper
June 25, 2018 Sophiris provides interim Topsalysin Phase 2b Clinical Trial Update http://investor.sophirisbio.com/events/event-details/sophiris-provides-interim-topsalysin-phase-2b-clinical-trial-update
June 25, 2018, Sophiris Reports Top-Line Interim Safety and Biopsy Findings For its Phase 2b Clinical Trial of Topsalysin in Localized Prostate Cancer http://investor.sophirisbio.com/news-releases/news-release-details/sophiris-bio-reports-top-line-interim-safety-and-biopsy-findings
June 13, 2018, Seeking Alpha; Sophiris: Upcoming Release For Top Line Data In Phase 2b Prostate Cancer Trial https://seekingalpha.com/article/4181303-sophiris-upcoming-release-top-line-data-phase-2b-prostate-cancer
May 14th, 2018, Sophiris Bio Reports 1st. Quarter 2018 and Key Corporate Highlights http://investor.sophirisbio.com/news-releases/news-release-details/sophiris-bio-reports-first-quarter-2018-financial-results-and
May 7th, 2018, Why I’m Bullish On Sophiris Bio’s Upcoming PH2B Data Release https://seekingalpha.com/article/4170694-bullish-sophiris-bios-upcoming-phase-2b-data-release
March 28, 2018, 17th Annual Needham Healthcare Conference, with Randy Woods http://wsw.com/webcast/needham86/sphs/
March 2nd, 2018 Randy Woods interview with Mike Ward at Biotech Showcase 2018Scroll down for a short video presentation: Understanding How Topsalysin Could Treat Both Localized Prostate Cancer and BPH http://www.sophirisbio.com/science/prostate-cancer/
January 8, 2018, Sophiris Bio Presents – 10th Annual Biotech Showcase Conference https://event.webcasts.com/viewer/event.jsp?ei=1175692&tp_key=076fc925c1
December 15, 2017, Order Granting Confidential Treatment Under the Securities Act 1933 https://www.sec.gov/Archives/edgar/data/1563855/999999999717010587/filename1.pdf
December 11, 2017, Sophiris Bio Announces Complete Enrollment in Phase 2b Topsalysin Study of Localized Prostate Cancer http://investor.sophirisbio.com/news-releases/news-release-details/sophiris-bio-announces-complete-enrollment-phase-2b-topsalysin
November 28, 2017, 29th Annual Piper Jaffray Healthcare Conference http://investor.sophirisbio.com/node/5821
November 20th, 2017, Zacks Small Cap Research, Financial Update http://scr.zacks.com/News/Press-Releases/Press-Release-Details/2017/SPHS-First-Dosing-in-Phase-2b-Trial-of-Topsalysin-in-Prostate-Cancer-Almost-Complete-Data-in-1H18-article/default.aspx?utm_content=buffered5e1&utm_medium=social&utm_source=twitter.com&utm_campaign=buffer
November 9, 2017, Sophiris Bio Reports Third Quarter Financial Results and Key Corporate Highlights. http://investor.sophirisbio.com/news-releases/news-release-details/sophiris-bio-reports-third-quarter-financial-results-and-key
October 11, 2017, Randy Woods; the Linkedin article speaks to Topsalysin’s phase 2a prostate cancer results and the need for focal therapy. https://www.linkedin.com/pulse/screen-prostate-cancer-definitely-what-do-results-thats-randall-woods/?trackingId=owdG3yRZMMkPg8FR24Nqbw%3D%3D
Bloomberg Snapshot http://www.investing.businessweek.wallst.com/research/stocks/snapshot/snapshot_article.asp?ticker=SPHS
October 2nd, 2017, Sophiris Bio Provides Enrollment Update on Topsalysin Phase 2b Study In Localized Prostate Cancer http://investor.sophirisbio.com/news-releases/news-release-details/sophiris-bio-provides-enrollment-update-topsalysin-phase-2b
September 13, 2017, Sophiris Bio Secures up to $10 Million in Term Loans from Silicon Valley Bank http://investor.sophirisbio.com/news-releases/news-release-details/sophiris-bio-secures-10-million-term-loans-silicon-valley-bank
September 2017, Investor Presentation http://investor.sophirisbio.com/static-files/f4ad8cbb-c1ba-4732-9f6f-9e4b1ae2758e
August 16, 2017, Recruiting update for Phase IIb Trial measuring the effectiveness of Topsalysin on early but significant prostate cancer tumors: Fort Lauderdale Florida, Ocala Florida, Temple Texas, London UK, and Southhampton, United Kingdom. https://clinicaltrials.gov/ct2/show/NCT03081481?term=topsalysin&rank=2
August 15, 2017, Zacks Small-Cap Research Updates Sophiris Bio http://s1.q4cdn.com/460208960/files/News/2017/August-15-2017_SPHS_Bautz.pdf
August 10, 2017, Second Quarter Financial Results and Key Corporate Highlights http://investor.sophirisbio.com/news-releases/news-release-details/sophiris-bio-reports-second-quarter-financial-results-and-key-0
July 25, 2017, Doctors trial ‘breakthrough’ injection for prostate cancer. http://www.uhs.nhs.uk/AboutTheTrust/Newsandpublications/Latestnews/2017/July-2017/Doctors-trial-breakthrough-injection-for-prostate-cancer.aspx
July 22, 2017, MailOnline article featuring Topsalysin prostate cancer treatment. http://www.dailymail.co.uk/health/article-4721086/Jab-prostate-cancer-spares-men-impotence.html
July 4, 2017, European Association of Urology http://www.europeanurology.com/article/S0302-2838(17)30583-3/pdf
June 27, 2017, Seeing Hard to Reach Prostate Cancer Makes it Easier to Treat, https://www.linkedin.com/pulse/seeing-hard-reach-prostate-cancer-makes-easier-treat-randall-woods-1?trk=v-feed&lipi=urn%3Ali%3Apage%3Ad_flagship3_feed%3BeVJI32Dcuwmm2v%2FAsM2yIA%3D%3D
June 23, 2017, Sophiris Bio Added to Russel Microcap Index http://investor.sophirisbio.com/news-releases/news-release-details/sophiris-bio-added-russell-microcap-index
June 15, 2016, Antihydrogen’s Notes on Sophiris Bio’s Product Market https://justpaste.it/17u31
June 8, 2017, Sophiris Bio begins dosing in the Prostate Cancer Phase 2b Clinical Trial http://investor.sophirisbio.com/news-releases/news-release-details/sophiris-bio-announces-first-patient-has-been-dosed-phase-2b
May 23, 2017, Sophiris Bio, Provides Update on Phase 2b Study of Topsalysin in Localized Prostate Cancer http://investor.sophirisbio.com/news-releases/news-release-details/sophiris-bio-provides-update-phase-2b-study-topsalysin-localized
May 15, 2017, Sophiris Bio, Quarterly Report – SEC Filing http://investor.sophirisbio.com/news-releases/news-release-details/sophiris-bio-reports-first-quarter-financial-results-and-key
May 12, 2017, – Notes on patents regarding Topsalysin (PRX-302).
May 12, 2017, – Patent notes regarding Topsalysin (PRX-302) continued.
May 12, 2017, – Patent notes regarding Topsalysin (PRX-302) continued.
Insider holdings as of April 2017
April 19th, 2017, Sophiris Bio management to meet with Needham https://thefly.com/news.php?fecha=2017-04-19&&symbol=SPHS
March 27, 2017, Sophiris Bio Reports Fourth Quarter and Full-Year 2016 Financial Results and Key Corporate Highlights http://investor.sophirisbio.com/news-releases/news-release-details/sophiris-bio-reports-fourth-quarter-and-full-year-2016-financial
U.S. Securities and Exchange Commission Archived Edgar Files https://www.sec.gov/Archives/edgar/data/1563855/000143774916037922/ex99-1.htm
Dr. Samuel Ray Denmeade is a Professor of Oncology, Urology, Pharmacology and Molecular Sciences at Johns Hopkins University School of Medicine. For more on Dr. Sam Denmeade as co-inventor of PRX302 and his current relationship to Sophiris Bio Inc, please visit: http://charts.stocktwits.com/production/original_75627759.png?1488082250
February 20, 2017 Dr. Sam Denmeade MD, Bipolar Androgen Therapy Presentation
January 20, 2017 ‘Huge leap’ in prostate cancer testing. http://www.bbc.com/news/health-38665618
January 5th, 2017 Seeking Alpha Article – Sophiris Bio Future Bio Tech http://seekingalpha.com/article/4034477-sophiris-bio-future-biotech-blockbuster-just-internet-memes
November 9, 2016 Sophiris Bio Reports Third Quarter 2016 and Key Business Highlights http://investor.sophirisbio.com/news-releases/news-release-details/sophiris-bio-reports-third-quarter-2016-financial-results-and
October 16, 2016 Eye opening studies on prostate cancer. http://www.news.cornell.edu/stories/2016/10/gene-drives-aggressive-prostate-cancer-identified
October 14, 2016 Sophiris Bio appoints Allison Hulme Ph.D., to the Board of Directors https://www.sec.gov/Archives/edgar/data/1563855/000143774916039831/sphs20161013_8k.htm
October 10, 2016 Sophiris Bio: How Far Off Is Topsalysin’s FDA Application?http://seekingalpha.com/article/4011293-sophiris-bio-far-topsalysins-fda-application
September 15, 2016 Roth Capital Initiates Buy on Sophiris http://www.smarteranalyst.com/2016/09/15/roth-capital-initiates-buy-sophiris-bio-inc-sphs-heres/
August 26, 2016 Sophiris Bio Closes Underwritten Public Offering. http://investor.sophirisbio.com/news-releases/news-release-details/sophiris-bio-closes-underwritten-public-offering
August 23, 2016 Sophiris Bio Prices Public Offering of Common Shares and Warrants. http://investor.sophirisbio.com/news-releases/news-release-details/sophiris-bio-prices-public-offering-common-shares-and-warrants
August 22, 2016 Sophiris Bio Announces Proposed Public Offering of Common Shares and Warrants. http://investor.sophirisbio.com/news-releases/news-release-details/sophiris-bio-announces-proposed-public-offering-common-shares
August 12, 2016 The Wall Street Transcript Interview with the President and CEO of Sophiris Bio Inc. Randall E. Woods https://www.twst.com/interview/interview-with-the-president-and-ceo-sophiris-bio-inc-nasdaqsphs
August 9th, 2016 Sophiris Bio Second Quarter 2016 Results and Key Business Highlights http://investor.sophirisbio.com/news-releases/news-release-details/sophiris-bio-reports-second-quarter-2016-financial-results-and
Article: August 4, 2016 – Is Sophiris Bio Inc. Primed for Acquisition? http://www.streetviewtraders.com/single-post/2016/08/04/Is-Sophiris-Bio-Inc-SPHS-Primed-for-Acquisition
June 13, 2016, Bioworld Today, Sophiris wows Street with prostate cancer data: http://www.bioworld.com/report/BWT061316Sophiris.pdf
June 9th, 2016: Sophiris Bio reports successful results from completed phase 2a study of topsalysin in localized prostate cancer: http://files.shareholder.com/downloads/AMDA-1OKDCO/4430554665x0x896421/9AD5C826-51CB-46C3-B436-FA6772D3C30F/SPHS-Transcript-2016-06-09T21_00_updated.pdf
May 12, 2016: the company engaged Oppenheimer & Co. Inc. , as its financial advisor, to assist with the evaluation of strategic alternatives, to advance the development of topsalysin and enhance shareholder value, including potential partnering arrangements, financings or a strategic transaction. http://investor.sophirisbio.com/news-releases/news-release-details/sophiris-bio-engages-oppenheimer-co-advise-strategic
Alternative Medications: http://www.fiercepharma.com/special-report/xtandi-medivation-and-astellas-pharma
Medications for Prostate Cancer; Drugs Associated with Prostate Cancer: https://www.drugs.com/condition/prostate-cancer.html?category_id=&include_rx=true&include_otc=true&show_off_label=true&submitted=true
Overview Article: May 25, 2016 Bruce V. Bigelow http://www.xconomy.com/san-diego/2016/05/25/sophiris-streamlines-operations-weighs-options-on-prostate-drug/?single_page=true#
December 16, 2014 Interim Data Disappoints, But is Ain’t Over Yet, Says Maxim http://www.smarteranalyst.com/2014/12/16/sophiris-interim-data-disappoints-aint-yet-says-maxim/
June 26, 2014 Sophiris Bio Inc., In the pipeline; A new take on BPH http://www.biospace.com/News/small-but-tenacious-two-of-san-diegos-emerging/338228
August 23, 2013 Sophiris Bio Closes $65 Million Public Offering http://investor.sophirisbio.com/news-releases/news-release-details/sophiris-bio-closes-65-million-public-offering
August 16, 2013, Sophiris Bio Prices its Previously Announced Public Offering of Common Shares http://investor.sophirisbio.com/news-releases/news-release-details/sophiris-bio-prices-its-previously-announced-public-offering
August 12, 2013 Sophiris Bio Announces Share Consolidation http://investor.sophirisbio.com/news-releases/news-release-details/sophiris-bio-announces-share-consolidation
April 2, 2012 Protox Therapeutics Changes Name to Sophiris Bio Inc. http://investor.sophirisbio.com/news-releases/news-release-details/protox-now-sophiris-bio
April 29, 2010 Protox signs $75 million license agreement with Kissei for commercialization of PRX302 in Japan for BPH and prostate disease http://www.newswire.ca/news-releases/protox-signs-75-million-license-agreement-with-kissei-for-commercializationof-prx302-in-japan-for-bph-and-prostate-disease-539757121.html
October 28, 2009 Luke Timmerman article on Randal Woods http://www.xconomy.com/san-diego/2009/10/28/sequel-pharmaceuticals-ceo-on-how-to-start-a-biotech-and-sell-it-for-a-bundle-and-repeat/
July 10, 2007, Phase 1 Prostate Cancer Study with PRX302 http://www.biospace.com/News/protox-therapeutics-inc-announces-positive/62356
November 14th, 2006 Scientists Design A PSA-activated Protoxin That Kills Prosate Cancer http://www.worldhealth.net/news/scientists_design_a_psa-activated_protox/
As a footnote below I would like to mention some famous and important people that died as the result of prostate cancer. Some of these people managed to live a long and successful life despite having prostate cancer and some did not. It is hoped that with the aging population that significant importance be placed on “fast tracking” any safe, responsible solution to prostate cancer.
Dan Fogelberg: Musician aged 56. Dennis Hopper: Actor aged 74. Bill Bixby: Actor aged 59. Merv Griffin: Actor aged 82. Pierre Trudeau: Prime Minister aged 80. Frank Zappa: Musician aged 52. Mark Dailey: Broadcaster aged 57. Jack Layton: Canadian Political Leader of the Opposition aged 61. http://www.ranker.com/list/famous-people-who-died-of-prostate-cancer/reference
Join in on a discussion about Sophiris Bio Inc.: http://stocktwits.com/symbol/SPHS http://finance.yahoo.com/mb/SPHS/ http://investorshub.advfn.com/Sophiris-Bio-Inc-SPHS-27046/ http://investorshangout.com/Sophiris-Bio-Inc-SPHS70960/ http://www.stockhouse.com/companies/bullboard?symbol=sphs
Disclaimer:
Please do your own due diligence. We are not investment advisors and suggest that anyone contemplating an investment, seek the advise of an investment professional.
________________________________________________________________________________________
Sophiris Bio SPHS Background 
